Astrazeneca (AZN) Cash from Financing Activities (2009 - 2026)

Astrazeneca's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $267.0 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 109.86% year-over-year to $267.0 million; the TTM figure through Mar 2026 stood at -$4.6 billion (up 47.66% YoY), while the FY2025 annual figure was -$7.5 billion, down 88.79% from the prior year.
• Cash from Financing Activities was $267.0 million for Q1 2026 at Astrazeneca, up from -$3.3 billion in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $2.0 billion in Q1 2024 to a low of -$4.1 billion in Q3 2024.
• Historically, Cash from Financing Activities has averaged -$1.5 billion across 5 years, with a median of -$1.5 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 199.85% in 2024, then slumped 389.12% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$1.3 billion in 2022, then decreased by 17.3% to -$1.5 billion in 2023, then soared by 55.83% to -$671.0 million in 2024, then plunged by 389.12% to -$3.3 billion in 2025, then jumped by 108.14% to $267.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $267.0 million (Q1 2026), -$3.3 billion (Q4 2025), and -$2.1 billion (Q3 2025), per Business Quant data.